About Alamar Biosciences
Alamar Biosciences is a publicly listed company based in Fremont (United States) founded in 2018 by Steve Chen and Yuling Luo. Ultra-high sensitivity protein analysis solutions are provided across multiplex levels. Alamar Biosciences has raised $230 million across 4 funding rounds from investors including HHS, Qiming Venture Partners and Sands Capital. Its chief executive, as recorded, is Yuling Luo. Its website alamarbio.com draws about 27 thousand monthly visits. Alamar Biosciences offers products and services including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is Alamar Biosciences, Inc. Its competitors include Sequenta, Glympse Bio and Crescendo Bioscience; 3 of its 3 listed competitors have raised funding.
Company details
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The companys proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
- Headquarters Fremont, United States
- Founders Steve Chen, Yuling Luo
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website alamarbio.com
- Social LinkedIn X Facebook
- Legal Name Alamar Biosciences Inc
- Total Equity Funding$230M (USD)
in 4 rounds
- Latest Funding Round$50M (USD), Series C
Jan 2026
- InvestorsHHS
& 8 more
Products & Services of Alamar Biosciences
Alamar Biosciences offers a comprehensive portfolio of products and services, including NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology.
Enables sensitive detection of protein biomarkers in fluid samples.
Automates proteomics analysis for efficient biomarker research.
Facilitates profiling of immunological protein biomarkers accurately.
Supports detection of neurological biomarkers for disease studies.
Aids in analyzing oncological protein biomarkers for research.
Funding Insights of Alamar Biosciences
Alamar Biosciences has successfully raised a total of $230M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $230M
- Total Rounds 4
- Last Round Series C — $50M
- First Round $321,869
(Jul 2020)
- Investors Count 9
All 4 funding rounds of Alamar Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $50M | Series C | – | – | |
| Feb 2024 | $100M | Series C | – | Sands Capital | – |
| Sep 2021 | $80M | Series B | – | Sherpa Healthcare Partners | |
| Jul 2020 | $321,869 | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Alamar Biosciences
Alamar Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Qiming Venture Partners and Sands Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| sherpahp.com | ||||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Active, long-term growth equity investments are provided globally. | sandscapital.com | Arlington, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| troweprice.com | ||||
| braidwell.com |
Investor details for Alamar Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alamar Biosciences
55 people are tracked at Alamar Biosciences (24 in leadership, 31 in team).
| Name | Role | Group |
|---|---|---|
Steve Chen | Co-Founder | Leadership |
Yuling Luo | Co-Founder & CEO | Leadership |
Brad Nawa | Director West | Leadership |
Douglas Hinerfeld | Senior Director Of Application Support | Leadership |
Anna Berdine | Senior Vice President Marketing | Leadership |
April Falcone | Sr. Director, Commercial Marketing | Leadership |
Alex Forrest-Hay | Senior Vice President Of Global Sales | Leadership |
Merinda Do, SPHR | Head of Human Resources | Leadership |
Christopher Bunker, Ph.D., M.B.A. | Vice President, Biopharma Business Development | Leadership |
Peter Vuong | Vice President Of Product Management & Global Support | Leadership |
Dan Z. | Vice President of Operations | Leadership |
Tod White | Chief Financial Officer & Chief Business Officer | Leadership |
Xiao-Jun Ma | Chief Technology Officer | Leadership |
Yiyuan Yin | Co-founder, VP of Technology | Leadership |
Justin McAnear | Chief Financial Officer | Leadership |
Matt Stanley | Director Service Support | Leadership |
Barry Lynch | Director of Business Development (EMEA) | Leadership |
Michael Evans | European Sales Director | Leadership |
Max Mahoney | Regional Sales Director- East | Leadership |
Cameron McKenzie | Vice President Of Commercial Operations | Leadership |
35 more people are available in the full profile.
Complete people profiles for Alamar Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Alamar Biosciences
Alamar Biosciences is a publicly listed company on the NASDAQ with ticker symbol ALMR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Apr 2026
- Listed onNASDAQ: ALMR
- Listed entityALAMAR BIOSCIENCES INC
- Exchange sectorHealth technology
- ISINUS0109111056
- Share price$23.52 (-2.97% on the day) · 2026-10-13
- Market capitalisation$1.63B
- Volume (last session)755,944
Timeline of Alamar Biosciences
4 dated milestones of Alamar Biosciences across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Alamar Biosciences is founded.
- Funding First funding round of $322K.
- Funding Latest funding round, Series C, of $50.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Alamar Biosciences
Alamar Biosciences has 3 listed competitors in our database, 3 of them funded. They include Sequenta, Glympse Bio and Crescendo Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| glympsebio.com | 2015 | Cambridge, United States | $79.39M | 21 | Multiple human diseases are monitored noninvasively through urine-based analysis. | |
| crescendobio.com | 2002 | San Francisco, United States | $122.05M | 128 | Molecular tests for autoimmune and inflammatory diseases are provided. |
Detailed competitors of Alamar Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alamar Biosciences
The website of Alamar Biosciences (alamarbio.com) receives about 27.2K visits a month and ranks #1,239,400 among all websites worldwide, #1,563 in Biotechnology and Pharmaceuticals.
- Monthly visits27.2K
▲ 18.4% vs previous month
- Unique visitors10.1K
per month
- Global rank#1,239,400
among all websites
- Category rank#1,563
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.8
- Average visit50 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with Alamar Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| wuxibiologics.com | 100% | 172.3K | #175,288 | View details | |
| seer.bio | 98% | 15.9K | #1,576,376 | View details | |
| mazetx.com | 93% | 9.2K | #2,405,150 | View details | |
| beckman.com | 53% | 213.1K | #216,799 | View details | |
south-bay-bio.com | south-bay-bio.com | 26% | #10,446,719 | – |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Alamar Biosciences (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alamar Biosciences
Complete news archive for Alamar Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alamar Biosciences
Alamar Biosciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alamar Biosciences is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Yuling Luo is the CEO of Alamar Biosciences, as recorded in our data. They have also founded this company.
Alamar Biosciences is a funded company, having raised a total of $230M across 4 funding rounds to date. The company's 1st funding round was a Grant of $321.87K, raised on Jul 2020.
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The companys proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Alamar Biosciences's top competitors include Sequenta, Glympse Bio and Crescendo Bioscience.
Alamar Biosciences offers NULISA Platform, ARGO HT System, NULISA Assays for Immunology, NULISA Assays for Neurology, and NULISA Assays for Oncology.
Yes, Alamar Biosciences is publicly traded on NASDAQ under the ticker symbol ALMR.
Alamar Biosciences has 9 investors. Key investors include HHS, Qiming Venture Partners, Sands Capital, Sherpa Healthcare Partners, and Morningside.
Alamar Biosciences operates through Alamar Biosciences, Inc..